Metabolon to Establish Metabolomics Lab in Qatar to Serve Markets in the Middle East

Metabolon, Inc., a global leader in metabolomics, has announced that it has entered a joint laboratory collaboration agreement with the Anti-Doping Laboratory Qatar (ADLQ), which operates an internationally accredited anti-doping laboratory, as well as toxicology and life sciences research services. ADLQ will establish Metabolon’s proprietary metabolomics platform in their Doha laboratory and serve academic and non-profit organizations throughout 13 countries in the Middle East.

The agreement enables ADLQ to promote Metabolon’s technology and precision medicine products for research use, as well as support population health studies throughout the region.

“The collaboration with ADLQ allows us to serve a new, significant market,” said Metabolon CEO John Ryals, PhD. “We will work with ADLQ to co-develop advanced anti-doping test methods and provide key researchers in the Middle East a more convenient site with access to Metabolon’s expertise. Metabolon now has established joint laboratory collaborations with premier institutions in Europe, China and the Middle East, and this pivotal relationship with ADLQ is another example of our commitment to expand Precision Metabolomics^™ applications for research and the clinic.”

“As the premier testing laboratory in the region, ADLQ has partnered with Weill Cornell Medicine-Qatar (WCM-Q) to establish the Metabolon platform in Doha to serve other researchers in the country and the region,” said ADLQ General Manager, Dr. Mohammed Alsayrafi. “This partnership is further strengthened by the involvement of Qatar Biomedical Research Institute (QBRI) at Hamad Bin Khalifa University (HBKU) and Interim Translational Research Institute (iTRI) at Hamad Medical Corporation. Contributions in the form of instrumentation for laboratory infrastructure from our partners have expedited the introduction of Metabolon’s cutting-edge metabolomics capabilities. ADLQ will host the laboratory facilities for conducting high-throughput metabolomics analysis for samples submitted by researchers. Currently, there are a number of researchers from local institutions that are utilizing Metabolon’s services, and the number is continually increasing. With such growing interest, but restricted sample transfer outside the country, it is deemed timely that such a platform be available locally. ADLQ has expertise and experience in mass spectrometry technology, as many of the services currently offered by ADLQ employ similar approaches.”

Development of the platform has already begun, and it is estimated to receive biological samples by the fourth quarter of 2017.